FDA Approves mFLUSIVA (influenza vaccine, mRNA) for the Prevention of Seasonal Influenza

Дата публикации: 05-08-2026 03:08:49

CAMBRIDGE, MA / ACCESS Newswire / August 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	New kind of flu shot is on the way as the FDA approves Moderna’s mRNA-based vaccine	0	7.46	06-08-2026
2	FDA approves first mRNA-based flu vaccine	0	9.2	06-08-2026
3	New Kind of Flu Shot Is on the Way as FDA Approves Moderna’s mRNA-Based Vaccine	0	10.21	06-08-2026
4	The FDA Approved a New mRNA Flu Vaccine. Here’s What to Know	0	10.12	10-08-2026
5	New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine	0	7.9	06-08-2026
6	FDA approves first mRNA flu vaccine	0	5.78	06-08-2026
7	FDA panel backs first-of-its-kind flu vaccine using mRNA technology	5	7	18-06-2026
8	FDA panel backs first-of-its-kind flu vaccine using mRNA technology	0	7	18-06-2026
9	FDA Approves Mucinex 12HR Cold & Fever Multi-Symptom (dextromethorphan, guaifenesin and naproxen) for Cold & Flu Symptoms	0	14.32	05-08-2026
10	В Подмосковье началась вакцинация от гриппа взрослого населения	0	0	28-08-2025

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10.86. Источник: www.drugs.com.